Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Research Center for Translational Medicine, Jinyintan Hospital, Wuhan, China.
J Thromb Haemost. 2020 Jun;18(6):1469-1472. doi: 10.1111/jth.14848. Epub 2020 May 4.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied.
To describe thrombocytopenia in patients with COVID-19.
For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100-150], or (150-) groups after taking the unit (×10 /L) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed.
Among all patients, 238 (16.1%) patients were deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia, and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5%, and 4.7% for (0, 50], (50, 100], (100-150], and (150-) groups, respectively. With (150-) as the reference, nadir platelet counts of (100-150], (50, 100], and (0, 50] groups had a relative risk of 3.42 (95% confidence interval [CI] 2.36-4.96), 9.99 (95% CI 7.16-13.94), and 13.68 (95% CI 9.89-18.92), respectively.
Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count, the higher the mortality becomes.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引起 2019 年新型冠状病毒病（COVID-19），目前正在全球迅速传播。COVID-19 患者的血小板减少尚未得到充分研究。
描述 COVID-19 患者的血小板减少症。
对来自中国武汉金银潭医院的 1476 例连续 COVID-19 患者，回顾性采集住院期间血小板计数的最低值，并在去除血小板计数最低值的单位（×10 / L）后将其分为（0，50]，（50，100]，（100-150]或（150-）组。分析血小板计数最低值和住院死亡率。
在所有患者中，有 238 例（16.1%）患者死亡，306 例（20.7%）有血小板减少症。与幸存者相比，非幸存者年龄较大，更可能发生血小板减少症，血小板计数最低值较低。（0，50]，（50，100]，（100-150]和（150-）组的住院死亡率分别为 92.1%，61.2%，17.5%和 4.7%。以（150-）为参照，血小板计数最低值分别为（100-150]，（50，100]和（0，50]组的相对风险为 3.42（95%置信区间[CI] 2.36-4.96），9.99（95%CI 7.16-13.94）和 13.68（95%CI 9.89-18.92）。
血小板减少症在 COVID-19 患者中很常见，并且与住院死亡率增加相关。血小板计数越低，死亡率越高。
